Egyptian International Pharmaceutical Industries Company (EGX: PHAR)

PHAR Statistics

Total Valuation

Egyptian International Pharmaceutical Industries Company has a market cap or net worth of EGP 6.72 billion. The enterprise value is 14.47 billion.

Market Cap	6.72B
Enterprise Value	14.47B

Important Dates

The last earnings date was Sunday, November 10, 2024.

Earnings Date	Nov 10, 2024
Ex-Dividend Date	n/a

Share Statistics

Egyptian International Pharmaceutical Industries Company has 148.76 million shares outstanding.

Current Share Class	n/a
Shares Outstanding	148.76M
Shares Change (YoY)	n/a
Shares Change (QoQ)	n/a
Owned by Insiders (%)	0.02%
Owned by Institutions (%)	0.16%
Float	56.10M

Valuation Ratios

The trailing PE ratio is 5.78.

PE Ratio	5.78
Forward PE	n/a
PS Ratio	0.96
PB Ratio	1.40
P/TBV Ratio	1.41
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 8.02, with an EV/FCF ratio of -3.95.

EV / Earnings	12.44
EV / Sales	2.07
EV / EBITDA	8.02
EV / EBIT	8.50
EV / FCF	-3.95

Financial Position

The company has a current ratio of 1.56, with a Debt / Equity ratio of 1.85.

Current Ratio	1.56
Quick Ratio	0.57
Debt / Equity	1.85
Debt / EBITDA	5.13
Debt / FCF	-2.42
Interest Coverage	2.15

Financial Efficiency

Return on equity (ROE) is 26.23% and return on invested capital (ROIC) is 9.00%.

Return on Equity (ROE)	26.23%
Return on Assets (ROA)	8.33%
Return on Capital (ROIC)	9.00%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.57
Inventory Turnover	1.37

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +11.59% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+11.59%
50-Day Moving Average	48.42
200-Day Moving Average	43.13
Relative Strength Index (RSI)	34.76
Average Volume (20 Days)	235,997

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Egyptian International Pharmaceutical Industries Company had revenue of EGP 7.00 billion and earned 1.16 billion in profits. Earnings per share was 7.82.

Revenue	7.00B
Gross Profit	3.11B
Operating Income	1.63B
Pretax Income	1.54B
Net Income	1.16B
EBITDA	1.73B
EBIT	1.63B
Earnings Per Share (EPS)	7.82

Balance Sheet

The company has 1.12 billion in cash and 8.87 billion in debt, giving a net cash position of -7.75 billion or -52.07 per share.

Cash & Cash Equivalents	1.12B
Total Debt	8.87B
Net Cash	-7.75B
Net Cash Per Share	-52.07
Equity (Book Value)	4.80B
Book Value Per Share	32.21
Working Capital	2.94B

Cash Flow

In the last 12 months, operating cash flow was -1.32 billion and capital expenditures -2.35 billion, giving a free cash flow of -3.66 billion.

Operating Cash Flow	-1.32B
Capital Expenditures	-2.35B
Free Cash Flow	-3.66B
FCF Per Share	-24.62

Margins

Gross margin is 44.37%, with operating and profit margins of 23.25% and 16.61%.

Gross Margin	44.37%
Operating Margin	23.25%
Pretax Margin	22.02%
Profit Margin	16.61%
EBITDA Margin	24.65%
EBIT Margin	23.25%
FCF Margin	-52.31%

Dividends & Yields

This stock pays an annual dividend of 1.00, which amounts to a dividend yield of 2.21%.

Dividend Per Share	1.00
Dividend Yield	2.21%
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	37.32%
Buyback Yield	n/a
Shareholder Yield	2.21%
Earnings Yield	17.31%
FCF Yield	-54.51%

Stock Splits

The last stock split was on February 28, 2019. It was a forward split with a ratio of 1.25.

Last Split Date	Feb 28, 2019
Split Type	Forward
Split Ratio	1.25

Scores

Egyptian International Pharmaceutical Industries Company has an Altman Z-Score of 1.6. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.6
Piotroski F-Score	n/a